NO20074267L - Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid - Google Patents

Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid

Info

Publication number
NO20074267L
NO20074267L NO20074267A NO20074267A NO20074267L NO 20074267 L NO20074267 L NO 20074267L NO 20074267 A NO20074267 A NO 20074267A NO 20074267 A NO20074267 A NO 20074267A NO 20074267 L NO20074267 L NO 20074267L
Authority
NO
Norway
Prior art keywords
biologically active
life
modified
polypeptide
conjugates
Prior art date
Application number
NO20074267A
Other languages
English (en)
Inventor
Marc Besman
Stewart Chipman
David Leung
Original Assignee
Cell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Therapeutics Inc filed Critical Cell Therapeutics Inc
Publication of NO20074267L publication Critical patent/NO20074267L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Sammendrag Angitt er biologisk aktive proteinkonjugater som omfatter et biologisk aktivt polypeptid koblet via en peptidbinding til et polypeptid omfattende fra 2 til omkring 500 enheter av et repeterende peptidmotiv, hvor det biologisk aktive proteinkonjugatet viser en modifisert plasmahalveringstid sammenlignet med den indre halveringstiden av det ikke-konjugerte biologisk aktive polypeptidet eller proteinet. Også angitt er fremgangsmåter for å lage og anvende de konjugerte proteinene, så vel som fremgangsmåter for å bestemme hvorvidt et gitt konjugat viser en modifisert halveringstid relativt til den indre halveringstiden av det ikke-konjugerte polypeptidet.
NO20074267A 2005-01-25 2007-08-21 Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid NO20074267L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US64711905P 2005-01-25 2005-01-25
US71258505P 2005-08-30 2005-08-30
PCT/US2006/002501 WO2006081249A2 (en) 2005-01-25 2006-01-25 Conjugates of biologically active proteins having a modified in vivo half-life

Publications (1)

Publication Number Publication Date
NO20074267L true NO20074267L (no) 2007-09-28

Family

ID=36644921

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074267A NO20074267L (no) 2005-01-25 2007-08-21 Konjugater av biologisk aktive proteiner som har en modifisert in vivo halveringstid

Country Status (14)

Country Link
US (2) US8129348B2 (no)
EP (1) EP1841787A2 (no)
JP (2) JP5735194B2 (no)
KR (1) KR101608083B1 (no)
CN (1) CN103172747A (no)
AU (1) AU2006208199B2 (no)
BR (1) BRPI0606934A2 (no)
CA (1) CA2595695A1 (no)
IL (1) IL184763A (no)
MX (1) MX2007008982A (no)
NO (1) NO20074267L (no)
NZ (1) NZ556726A (no)
RU (1) RU2007132188A (no)
WO (1) WO2006081249A2 (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ556726A (en) * 2005-01-25 2011-04-29 Cell Therapeutics Inc Conjugates of biologically active proteins having a modified in vivo half-life
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
DK2402754T4 (da) * 2006-03-06 2023-08-28 Amunix Operating Inc Ustrukturerede rekombinante polymerer og anvendelser deraf
EP2402754B2 (en) † 2006-03-06 2023-07-26 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US8592374B2 (en) 2007-03-16 2013-11-26 Research Foundation For Mental Hygiene, Inc. Neurotrophic peptides
EP2009103A1 (en) * 2007-03-16 2008-12-31 Ebewe Pharma Ges.m.b.H. Nfg. KG Neurotrophic peptides
AU2013203326B2 (en) * 2007-06-21 2013-08-01 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
MX2010001684A (es) 2007-08-15 2010-04-21 Amunix Inc Composiciones y metodos para modificar propiedades de polipeptidos biologicamente activos.
WO2009026729A1 (en) * 2007-08-30 2009-03-05 University Of Waterloo Amino acid pairing-based self assembling peptides and methods
JP5730781B2 (ja) 2008-12-29 2015-06-10 ロンザ・ブレーヌ・エスエーＬｏｎｚａ Ｂｒａｉｎｅ Ｓａ ビバリルジンの製造方法
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
JP5499296B2 (ja) * 2009-02-03 2014-05-21 国立大学法人東京農工大学 細胞の吸着を制御可能なポリペプチド
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
JP5839597B2 (ja) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド グルコース調節ポリペプチド並びにその作成及び使用方法
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN102741275B (zh) 2009-08-24 2016-08-03 阿穆尼克斯运营公司 凝血因子ix组合物及其制备和使用方法
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
MX338914B (es) 2010-05-21 2016-05-06 Xl Protein Gmbh Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos.
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
NZ611076A (en) 2010-12-01 2015-09-25 Alderbio Holdings Llc Anti-ngf compositions and use thereof
WO2013024049A1 (en) 2011-08-12 2013-02-21 Ascendis Pharma A/S Protein carrier-linked prodrugs
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
LT3564260T (lt) 2012-02-15 2023-01-10 Bioverativ Therapeutics Inc. Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai
CA2865578C (en) 2012-02-27 2023-01-17 Amunix Operating Inc. Xten conjugate compositions and methods of making same
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
EP2914728B1 (en) 2012-11-01 2020-07-08 Factor Bioscience Inc. Methods and products for expressing proteins in cells
TWI667255B (zh) 2013-08-14 2019-08-01 美商生物化學醫療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016131052A1 (en) 2015-02-13 2016-08-18 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN104988107B (zh) * 2015-05-19 2018-06-08 中国农业科学院兰州兽医研究所 一种高效表达口蹄疫病毒抗原基因的重组乳酸杆菌及其制备方法和应用
CN107743494B (zh) * 2015-06-02 2022-04-29 诺和诺德股份有限公司 具有极性重组延伸体的胰岛素
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods of making and using same
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
EP3355931B1 (en) 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
IL308824A (en) 2016-08-17 2024-01-01 Factor Bioscience Inc Nucleic acid products and methods of administration thereof
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
CA3049806A1 (en) 2017-01-30 2018-08-02 Alexion Pharmaceuticals, Inc. Monovalent anti-properdin antibodies and antibody fragments
MA49339A (fr) 2017-04-05 2020-02-12 Novo Nordisk As Conjugués insuline-fc à extension oligomère
JP2021507706A (ja) 2017-12-21 2021-02-25 アムニクス ファーマシューティカルズ， インコーポレイテッド 放出セグメントおよびそれを含む結合組成物
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
JP7699552B2 (ja) 2019-07-03 2025-06-27 ファクター バイオサイエンス インコーポレイテッド カチオン性脂質及びその使用
US10501404B1 (en) 2019-07-30 2019-12-10 Factor Bioscience Inc. Cationic lipids and transfection methods
CN114641484B (zh) * 2019-11-05 2024-08-09 国立大学法人京都大学 肽、组合物及治疗、预防或改善心境障碍的方法
CN112608366B (zh) * 2020-12-31 2024-08-30 中国药科大学 超正电荷聚多肽及其制备方法、应用
CN113480667B (zh) * 2021-08-17 2023-03-28 长春萤火虫生物科技有限公司 一种人粒细胞集落刺激因子突变体重组融合蛋白及其制备方法和应用
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone
EP4635970A1 (en) * 2022-12-16 2025-10-22 Toagosei Co., Ltd. Synthetic peptide and construct
WO2025065355A1 (zh) * 2023-09-27 2025-04-03 京东方科技集团股份有限公司 针对亨廷顿舞蹈症的早期诊断的多肽探针和试剂盒

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
ATE148171T1 (de) * 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6455678B1 (en) 1996-04-26 2002-09-24 Amcell Corporation Human hematopoietic stem and progenitor cell antigen
CN1240479A (zh) * 1996-07-09 2000-01-05 安姆根有限公司 截短的可溶性肿瘤坏死因子i－型和ii－型受体
AU7266698A (en) * 1997-04-30 1998-11-24 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
WO2000042560A2 (en) 1999-01-19 2000-07-20 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
AU2001267337A1 (en) * 2000-06-30 2002-01-14 Maxygen Aps Peptide extended glycosylated polypeptides
EP1497331A2 (en) 2002-01-14 2005-01-19 William Herman Multispecific binding molecules
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
CN101111516B (zh) * 2005-01-25 2013-02-27 细胞治疗学公司 体内半衰期改变的生物活性蛋白质偶联物
NZ556726A (en) * 2005-01-25 2011-04-29 Cell Therapeutics Inc Conjugates of biologically active proteins having a modified in vivo half-life

Also Published As

Publication number Publication date
WO2006081249A8 (en) 2007-09-13
US8748577B2 (en) 2014-06-10
JP2008528002A (ja) 2008-07-31
JP2013100292A (ja) 2013-05-23
US8129348B2 (en) 2012-03-06
BRPI0606934A2 (pt) 2017-07-11
IL184763A0 (en) 2007-12-03
AU2006208199A1 (en) 2006-08-03
IL184763A (en) 2013-05-30
US20090298762A1 (en) 2009-12-03
RU2007132188A (ru) 2009-03-10
KR101608083B1 (ko) 2016-04-01
CN103172747A (zh) 2013-06-26
MX2007008982A (es) 2007-12-06
WO2006081249A2 (en) 2006-08-03
US20120252717A1 (en) 2012-10-04
WO2006081249A3 (en) 2007-02-01
JP5735194B2 (ja) 2015-06-17
CA2595695A1 (en) 2006-08-03
AU2006208199B2 (en) 2012-06-07
NZ556726A (en) 2011-04-29
KR20070119622A (ko) 2007-12-20
EP1841787A2 (en) 2007-10-10
WO2006081249A9 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
WO2006081249A3 (en) Conjugates of biologically active proteins having a modified in vivo half-life
ES2397852T3 (es) Antagonistas y conjugados de péptidos CGRP
UA96916C2 (ru) Конъюгат полипептида и синтетически сульфатованого пентасахарида, фармацевтическая композиция на его основе
WO2005055950A3 (en) Glycopegylated factor ix
NO20080970L (no) Glykopegylert faktor VII og faktor VIIA
CY1119243T1 (el) Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf
SI1180121T1 (en) Long lasting insulinotropic peptides
EP2514757A3 (en) Glycopegylated granulocyte colony stimulating factor
WO2005055946A3 (en) Glycopegylated granulocyte colony stimulating factor
WO2005056760A3 (en) Glycopegylated follicle stimulating hormone
BRPI0717505B8 (pt) conjugado de peptídeo e formulação farmacêutica
WO2006031811A3 (en) Glycopegylated interferon alpha
DK1329458T3 (da) Peptider som sænker blodglucoseniveauer
SE9901379D0 (sv) Receptor structures
EP3118218A3 (en) Fusion proteins for blood-brain barrier delivery
FI20050932A7 (fi) Heterobifunktionaaliset polymeeriset biokonjugaatit
MXPA03011094A (es) Citotoxinas, profarmacos, ligadores, y estabilizadores utiles para ello.
WO2006127910A3 (en) Glycopegylated erythropoietin formulations
LU91989I2 (fr) Bydureon
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
WO2003049684A3 (en) Pseudo-antibody constructs
WO2006113681A3 (en) Plant-derived elastin binding protein ligands and methods of using the same
WO2007067979A3 (en) Targeting vector-phospholipid conjugates
DK1641820T3 (da) Fra RasGap afledt peptid til selektiv at dræbe kræftceller
ES2950137T3 (es) Análogos de hAM15-52 con potencia mejorada frente al receptor de amilina (hAMY3R)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application